ROSA Total Knee Post Market Study EMEA
| 対象疾患 | Knee Pain, Chronic Osteoarthritis, Avascular Necrosis of the Femoral Condyle, Moderate Varus, Valgus or Flexion Deformities |
|---|---|
| 相 | 該当なし |
| スポンサー | Zimmer Biomet |
| ステータス | 完了 |
| 参加者数 | 252 名 |
| 介入（薬剤） | Device: Persona Total Knee, Device: NexGen Total Knee, Device: Vanguard Total Knee |
| 開始日 | 2020年12月15日 |
| 完了日 | 2025年8月22日 |
| 結果公開日 | 2026年1月21日 |
概要
This is a prospective, multicenter clinical study designed to facilitate the collection and evaluation of surgical workflow efficiency, patient pain and function outcome and adverse events data. This study might include Persona, Nexgen and Vanguard product families using the ROSA Total Knee Robotic system or conventional instrumentation. The primary objective is to evaluate the accuracy of implant alignment for ROSA Total Knee robotic instrumentation compared to conventional instrumentation.
Alignment Accuracy
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Dietary Salt in Rheumatoid Arthritis — Vanderbilt University Medical Center
- Feasibility and Acceptability of PREVAIL (PREserving Valued Activities In Life) — University of North Carolina, Chapel Hill
- Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With R — Alfasigma S.p.A.
- CD40L Antagonism in Rheumatoid Arthritis (RA) — National Institute of Allergy and Infectious Diseases (NIAID)
- A Study of Baricitinib in Participants With Rheumatoid Arthritis — Eli Lilly and Company
- A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis — Eli Lilly and Company